Re:Startups from Y Combinator’s S19 Demo Day 2
by wiggles_md on Wednesday August 21, 2019 @10:16AM
(#20757365)
Your link is to the patent application. If you check PAIR, you’ll see that only a small subset of the claims, amended, have received NOA. I would tend to disagree about the strength of their IP portfolio based on a cursory glance at the publicly available info, but I’d be curious to hear why you think differently.
Re:Startups from Y Combinator’s S19 Demo Day 2
by DrAwdeOccarim on Wednesday August 21, 2019 @03:39PM
(#20760839)
Ouch, I didn't look at PAIR. They lost all their delivery claims. I was impressed by their priority date, which pre-dates some of the competition, but it looks like they lost most of the key claims they'll need to fight off a lawsuit.
Re:Startups from Y Combinator’s S19 Demo Day 2
by johnramunas on Wednesday November 18, 2020 @05:27PM
(#25143348)
Hi Guys, Thanks for your interest! An update from Rejuvenation Technologies: The comment above is incorrect. Our claims were simply moved to a continuation patent, US 16/735,681, which has been granted, and our granted patents now cover all in vitro and in vivo applications of TERT mRNA-based telomere extension. If you'd like more info, please feel free to email [email protected]. Thanks again! Best regards, John
I hope they can get this to work! The issue is their paper uses technology covered by other players in the space who have a decade head start and significant research budgets. Maybe they'll get bought out, but my guess is delivery and CMC are hurdles they'll run up against and then have a hard time getting follow-on investors. FIH for this idea is going to be really hard. If they can get this going, I'd love to see adding in additional components of the telomerase holoenzyme.
Edit - Their IP position is actually pretty strong and they are already thinking about delivering the other holoenzyme components: https://patents.google.com/patent/US20140242155A1
I hope they lean on the exosome delivery idea discussed within, "In highly preferred embodiments, the delivery vehicle is an exosome". That would really differentiate them from the competition. The real test will be biodistribution in non-rodent models. I will be following closely!